New PPARα/γ/δ optimal activator rationally designed by computational methods

Elias C. Padilha, Rodolfo B. Serafim, Deisy Y.R. Sarmiento, César F. Santos, Cleydson B.R. Santos, Carlos H.T.P. Silva

Research output: Articles / NotesScientific Articlepeer-review

18 Scopus citations


The peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor that acts as a transcription factor, regulating glucose, lipid and inflammation signaling and it is exploited in type 2 diabetes treatment. However, the selective activation of this PPAR subtype has been linked to important adverse effects which can be mitigated through concomitant activation of PPARα and PPARδ. In this study, we proposed new PPARγ agonists using PharmaGist Server for pharmacophore prediction, the molecular docking was performed by GOLD (genetic optimization for ligand docking) v2.2, AutoDock 4.2 and AutoDock Vina 1.1 and QikProp v4.0 and Derek for absorption, distribution, metabolism, excretion and toxicity (ADMET) assessment. One molecule showed high predicted affinity to PPARδ and favorable pharmacokinetic and toxicity properties. It was then evaluated against PPARα and PPARδ and showed greater affinity to these receptors than the controls. Therefore this molecule is a promising drug lead for the development of derivatives and for the treatment of metabolic syndrome with the benefits of a PPAR pan activation.

Original languageEnglish
Pages (from-to)1636-1647
Number of pages12
JournalJournal of the Brazilian Chemical Society
Issue number9
StatePublished - 1 Sep 2016
Externally publishedYes


  • ADMET prediction
  • Molecular modeling
  • PPAR pan agonist
  • Type 2 diabetes


Dive into the research topics of 'New PPARα/γ/δ optimal activator rationally designed by computational methods'. Together they form a unique fingerprint.

Cite this